Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that women with androgenic alopecia in Patos, Brazil, experienced significant psychological and social impacts, including feelings of frustration, low self-esteem, and social withdrawal.

In this study, researchers found that sesamin, a component of sesamum, modulated the AR-MAPK-Wnt signaling pathway in DHT-stimulated HaCaT keratinocytes, demonstrating potential multi-target activity against molecular events in androgenetic alopecia.

This study found that topical cetirizine 1% significantly improved hair density and diameter in patients with androgenetic alopecia, with patients tolerating the treatment well.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

This case report describes a pregnant woman diagnosed with Cushing Syndrome, likely due to an adrenal tumor, whose condition worsened during hospitalization, resulting in heart failure, sepsis, and shock.

This article reviews the use of green tea for hair loss prevention and regrowth, highlighting its potential effects on dermal papillae, but reports no new clinical results.

In this study, androgenetic alopecia was linked to a higher likelihood of hyperlipidemia in both men and women and obesity in women, highlighting it as a potential marker for cardiometabolic risk.

This study found that 1mg/d oral finasteride was effective and safe for treating androgenetic alopecia in men, with better results observed in patients aged 26 or younger.

In this study, a group taking compound ginseng cicada decoction showed significantly lower relapse rates, severity, and itching related to atopic dermatitis over 3 months compared to a control group, and reported improved quality of life with no significant adverse events.

This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This review discusses the diagnosis and treatment of androgenetic alopecia, emphasizing the importance of realistic patient expectations due to the psychosocial impact of hair loss, and reports no new clinical results.

This research review discusses the potential link between androgenetic alopecia and increased cardiovascular risk but does not report any new experimental findings.

This review discusses the pathological factors and comorbidities associated with androgenetic alopecia and reports no new clinical results, emphasizing the need for improved understanding and treatment in clinical practice.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

This study found that a novel nano-engineered platform, PCA, significantly promoted hair regeneration in an androgenetic alopecia mouse model by enhancing angiogenesis and hair follicle stem cell proliferation, showing promise for future hair regrowth treatments.

This study found that while androgenetic alopecia was common and more frequent with age and in men within the PERSIAN Guilan Cohort, it was not independently associated with depression.

This case report describes an 8-year-old boy with acrodermatitis enteropathica who showed significant recovery from severe symptoms after receiving a therapeutic zinc supplement.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

In this review, the authors highlight that drugs promoting androgenic activity or inhibiting estrogenic activity may unmask or worsen androgenetic alopecia in genetically predisposed individuals, indicating the need for careful management in clinical settings.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

This study found that androgenetic alopecia significantly impacts young men's quality of life, affecting their self-esteem and daily functioning, and highlights the need for a specialized assessment tool.

This study investigates the potential of onion extract as a treatment for androgenetic alopecia by using in silico and ADME/T analyses to examine how active compounds from onions interact with the 5-alpha-reductase enzyme.

In this study, researchers at Jawaharlal Nehru Medical College are comparing the effectiveness and side effects of Adapalene gel (0.1%) and Tazarotene gel (0.05%) in acne treatment among patients aged 12-35, with assessments every 4, 8, and 12 weeks. Results are not reported yet.

This article reviews acromegaloid facial appearance syndrome and presents a case in a 57-year-old woman, emphasizing the need for more cases to understand its clinical features and inheritance patterns.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.